Cost-Effectiveness Analysis of Vedolizumab Compared With Infliximab in Anti-TNF-α-Naïve Patients With Moderate-to-Severe Ulcerative Colitis in China

Objective: To evaluate the cost effectiveness of vedolizumab vs. infliximab in the treatment of anti-tumor necrosis factor-alpha (TNF-α)-naïve patients with moderate-to-severe active ulcerative colitis (UC) in China. Methods: The costs and effectiveness of vedolizumab and infliximab in the treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Ting, Sheng, Yanan, Guan, Haijing, Meng, Rui, Wang, Zijing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417715/
https://www.ncbi.nlm.nih.gov/pubmed/34490187
http://dx.doi.org/10.3389/fpubh.2021.704889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8417715/
https://www.ncbi.nlm.nih.gov/pubmed/34490187
http://dx.doi.org/10.3389/fpubh.2021.704889

Ejemplares similares